Back to Search Start Over

Antihypertensive effect of telmisartan versus perindopril in hypertensive patients.

Authors :
Zhao D
Liu H
Chen S
Dong P
Source :
Bratislavske lekarske listy [Bratisl Lek Listy] 2023; Vol. 124 (5), pp. 380-386.
Publication Year :
2023

Abstract

Objective: We performed this meta-analysis determining the antihypertensive effect of telmisartan versus perindopril in patients with essential hypertension.<br />Background: The comparison of antihypertensive effects between telmisartan and perindopril were controversial.<br />Methods: Pubmed, Web of Science, and Cochrane Central were searched for all published studies.<br />Results: The antihypertensive effects were assessed in 753 patients included in 7 trials with a mean follow-up of 20 ± 16 weeks. There was no significant difference between telmisartan and perindopril in reduction of systolic blood pressure (SBP, weighted mean differences (WMD) 0.02 (95% confidence interval (CI), ‒2.78, 2.81) mm Hg, p > 0.05). The reduction of diastolic BP (DBP) treated with telmisartan was greater than perindopril in these patients (WMD ‒2.05 (95% CI, ‒2.60, ‒1.49) mm Hg, p < 0.001). Considering the effects of different doses on BP reduction, a sub-analysis was performed. The reduction of DBP treated with 40 mg/day telmisartan was greater than 4‒5 mg/day perindopril (WMD ‒2.18 (95% CI, ‒2.83, ‒1.53) mm Hg, p 0.05).<br />Conclusion: The reduction of DBP is greater treated with telmisartan than perindopril in patients with essential hypertension (Tab. 2, Fig. 4, Ref. 34). Text in PDF www.elis.sk Keywords: essential hypertension, blood pressure, telmisartan, perindopril, meta-analysis.

Details

Language :
English
ISSN :
0006-9248
Volume :
124
Issue :
5
Database :
MEDLINE
Journal :
Bratislavske lekarske listy
Publication Type :
Academic Journal
Accession number :
36876369
Full Text :
https://doi.org/10.4149/BLL_2023_058